COMPASS Pathways plc (NASDAQ:CMPS) Given Average Rating of “Buy” by Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have earned a consensus rating of “Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $21.83.

A number of brokerages have recently issued reports on CMPS. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday. Stifel Nicolaus initiated coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a “buy” rating and a $11.00 target price on the stock. Canaccord Genuity Group lowered their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Royal Bank of Canada restated an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a research note on Tuesday, March 4th.

COMPASS Pathways Price Performance

CMPS stock opened at $2.94 on Friday. The stock’s 50 day moving average is $3.86 and its two-hundred day moving average is $4.72. COMPASS Pathways has a 52-week low of $2.88 and a 52-week high of $10.31. The company has a market capitalization of $272.46 million, a PE ratio of -1.34 and a beta of 2.29. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). Analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP bought a new stake in COMPASS Pathways in the fourth quarter valued at $11,714,000. Altium Capital Management LLC bought a new stake in COMPASS Pathways in the 4th quarter valued at about $5,384,000. Nantahala Capital Management LLC boosted its stake in COMPASS Pathways by 400.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,780,000 after purchasing an additional 800,000 shares during the period. Tang Capital Management LLC bought a new position in COMPASS Pathways in the 4th quarter worth about $3,780,000. Finally, Affinity Asset Advisors LLC increased its stake in shares of COMPASS Pathways by 183.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company’s stock valued at $3,215,000 after purchasing an additional 550,000 shares during the period. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.